Affymetrix News

Thomas Weisel Partners William R. Quirk - Piper Jaffray Quintin J. Lai - Robert W. Baird Doug Schenkel - Cowen and Company Tycho W. Peterson - JP Morgan Isaac Ro - Leerink Swann Presentation Operator Good afternoon, my name is Kasey and I will be your conference operator today.

Affymetrix Inc., which makes genetic analysis technology, on Wednesday reported a narrower third-quarter loss, but the results missed Wall Street expectations, sending shares plunging in after-hours trading.

Affymetrix, Inc. today announced the launch of the Axiom Genotyping Solution, its next-generation array technology designed to match the significant rise in genetic content generated by government and privately funded sequencing projects.

Affymetrix, Inc. today announced that the Kaiser Permanente Research Program on Genes, Environment, and Health and the University of California at San Francisco have entered into an agreement with Affymetrix to support genome-wide analyses of DNA samples from 100,000 Kaiser Permanente members.

The Sacramento area was awarded almost $1 million in employment training funds in a new round of grants announced Friday by the state Employment Training Panel.

BeaconEquity.com announces an investment report featuring life sciences company Helicos BioSciences Corp.

Our analysts have issued free ratings reports on the following six companies: Affymetrix Inc.

Affymetrix, Inc. today announced that company management will provide a corporate overview at four conferences in September.

Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases -supported Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute today announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella.

Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases -supported Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute today announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella.

Affymetrix, Inc. and the National Institute of Allergy and Infectious Diseases -supported Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute today announced the launch of the Affymetrix FDA-ECSG custom microarray for identifying and discriminating between different strains of E. coli and Shigella.

This custom array was developed for the FDA and is now available to researchers worldwide.A Affymetrix and JCVI have collaborated to make this array available from the PFGRC at no cost to researchers through the NIAID-sponsored PFGRC microarray application process.

CiteULike is a free online bibliography manager. Register and you can start organising your references online.

Shares of the following companies are having unusual moves in U.S. trading this morning.

Shares of Affymetrix Inc., which makes genetic data analysis instruments, jumped Thursday after the company said it swung to a second-quarter profit on a debt buyback.

Affymetrix Inc. July 22, 2009 05:00 PM ET Executives Doug Farrell - Vice President Investor Relations and Treasury Kevin M. King - President and Chief Executive Officer John C. Batty - Chief Financial Officer and Executive Vice President of Finance Analysts Marshall Urist - Morgan Stanley Quintin J. Lai - Robert W. Baird & Co., Inc.

Affymetrix, Inc. today announced that it will release operating results for the second quarter of 2009 after close of the stock market on Wednesday, July 22, 2009.

Affymetrix, Inc. today announced that it will webcast its Annual Meeting of Shareholders live at 4 p.m. , on June 17, 2009.

This is a virus that scientists can love - and laugh with. CompareNetworks' video for Affymetrix.

Agilent Tech., Inc. v. Affymetrix, Inc. Agilent's microarray hybridization genetic analysis patent issued in 2003.